Efficacy of Immune Checkpoint Inhibition in RET Fusion Positive Non-Small Cell Lung Cancer Patients

被引：2
|
作者：
Sireci, A. [1 ]
Morosini, D. [1 ]
Rothenberg, S. [2 ]
机构：
[1] Loxo Oncol Inc, Med Affairs, Stamford, CT USA
[2] Loxo Oncol, Stamford, CT USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
RET-altered NSCLC; efficacy of checkpoint inhibitors; driver-positive NSCLC;
D O I：
10.1016/j.jtho.2019.08.816
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-101
引用
收藏
页码：S401 / S401
页数：1
相关论文
共 50 条
  • [1] Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer
    Bhandari, Naleen Raj
    Hess, Lisa M.
    Han, Yimei
    Zhu, Yajun E.
    Sireci, Anthony N.
    [J]. IMMUNOTHERAPY, 2021, 13 (11) : 893 - 904
  • [2] Immune checkpoint inhibitors for RET fusion non-small cell lung cancer: hopes and challenges
    Zhao, Lu
    Zhang, Jing
    Wang, Na
    Zhang, Dou
    Wang, Ziwei
    Yu, Yongchao
    Mei, Qingyun
    Liao, Dongying
    Jia, Yingjie
    Kong, Fanming
    [J]. ANTI-CANCER DRUGS, 2023, 34 (09) : 979 - 984
  • [3] SORAFENIB IN PATIENTS WITH RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
    Horiike, Atsushi
    Takeuchi, Kengo
    Uenami, Takeshi
    Kawano, Yuko
    Tanimoto, Azusa
    Kaburaki, Kyohei
    Kobayashi, Hiroshi
    Gyotoku, Hiroshi
    Nishizawa, Hironari
    Tambo, Yuichi
    Nakatomi, Katsumi
    Yanagitani, Noriko
    Ohyanagi, Fumiyoshi
    Hagiwara, Sachiko
    Motoi, Noriko
    Ishikawa, Yuichi
    Horai, Takeshi
    Nishio, Makoto
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S898 - S898
  • [4] Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer
    Zhou, Qing
    Zhao, Jun
    Chang, Jianhua
    Wang, Huijie
    Fan, Yun
    Wang, Ke
    Wu, Gang
    Nian, Weiqi
    Sun, Yuping
    Sun, Meili
    Wang, Xiangcai
    Shi, Huaqiu
    Zheng, Xiangqian
    Yao, Sheng
    Qin, Mengmeng
    Shen, Zhenwei
    Yang, Jason
    Wu, Yi-Long
    [J]. CANCER, 2023, 129 (20) : 3239 - 3251
  • [5] Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
    Horiike, Atsushi
    Takeuchi, Kengo
    Uenami, Takeshi
    Kawano, Yuko
    Tanimoto, Azusa
    Kaburaki, Kyohei
    Tambo, Yuichi
    Kudo, Keita
    Yanagitani, Noriko
    Ohyanagi, Fumiyoshi
    Motoi, Noriko
    Ishikawa, Yuichi
    Horai, Takeshi
    Nishio, Makoto
    [J]. LUNG CANCER, 2016, 93 : 43 - 46
  • [6] Reflections on immune checkpoint inhibition in non-small cell lung cancer
    Leventakos, Konstantinos
    Mansfield, Aaron S.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 411 - 413
  • [7] Immune checkpoint inhibition in elderly non-small cell lung cancer patients.
    Marrone, Kristen
    Zhang, Jiajia
    Feliciano, Josephine Louella
    Forde, Patrick M.
    Hann, Christine L.
    Kelly, Ronan Joseph
    Ettinger, David S.
    Turner, Michelle
    Rowe, Valerie
    Bonerigo, Sarah
    Smith, Kellie Nicole
    Anagnostou, Valsamo
    Velculescu, Victor E.
    Brahmer, Julie R.
    Naidoo, Jarushka
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [8] Efficacy of immune checkpoint inhibitors in younger patients with non-small cell lung cancer
    Shinkichi Takamori
    Mototsugu Shimokawa
    Takefumi Komiya
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 13175 - 13184
  • [9] Efficacy of immune checkpoint inhibitors in younger patients with non-small cell lung cancer
    Takamori, Shinkichi
    Shimokawa, Mototsugu
    Komiya, Takefumi
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (14) : 13175 - 13184
  • [10] Real-world outcomes of immune checkpoint inhibitors and selective RET inhibitors for RET fusion non-small cell lung cancer
    Wan, R.
    Duan, J.
    Wang, Z.
    Lin, L.
    Li, W.
    Jie, W.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S54 - S54
12345